Monopar Therapeutics
Monopar Therapeutics

Monopar Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

$523.3M

Market Cap • 10/2/2026

2014

(12 years)

Founded

2019

(7 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

19,5

EPS

—

Market Cap

Market Cap

523,3M

EV

389,2M

EV/Revenue

0

EV/EBITDA

-17,6

EV/EBIT

-17,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-17,4%

Total Yield

-17,4%

Payout

0%

Retained Earnings

-98,7M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,2%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

22,9%

CAGR Net Income 5Y

18,2%

CAGR EPS 5Y

-4,5%

CAGR OCF 5Y

15,7%

Leverage

N.D./EBITDA

6,1

Debt/Equity

0%

Current Ratio

33,6

Quick Ratio

33,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium